Dupixent Phase 3 Study Shows Promise for CSU Patients

A pivotal phase 3 study reveals Dupixent's significant impact on chronic spontaneous urticaria (CSU). The study, LIBERTY-CUPID Study C, demonstrated a near 50% reduction in itch and urticaria activity compared to placebo. Conducted on biologic-naïve patients, the study reinforces findings from a prior phase 3 trial.

CSU affects over 300,000 Americans, with treatments often failing to provide relief. If approved, Dupixent would be the first targeted therapy for CSU in a decade. Patients on Dupixent reported a notable 30% complete response rate compared to 18% for placebo. Adverse events were comparable between both groups.

Sanofi aims to submit data to the FDA for regulatory approval by year-end. These findings highlight the potential of Dupixent to address a critical unmet need for CSU patients globally.